RVMD Stock Forecast: Revolution Medicines, Inc. Price Predictions for 2026-2027
The 24 Wall Street analysts covering Revolution Medicines, Inc. hold a median 12-month price target of $272 — +68.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 56 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Revolution Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RVMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RVMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +68.6% from it.
Of the 20 most recent actions, 12 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $350 |
| 13 Nov 2026 | Morgan Stanley | Maintains | Overweight | $272 → $247 |
| 6 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $280 → $350 |
| 5 Nov 2026 | Evercore ISI Group | Maintains | Outperform | $320 → $340 |
| 5 Nov 2026 | Guggenheim | Maintains | Buy | $275 → $298 |
| 5 Nov 2026 | Piper Sandler | Maintains | Overweight | $210 → $222 |
| 5 Nov 2026 | RBC Capital | Maintains | Outperform | $260 → $321 |
| 5 Nov 2026 | TD Cowen | Maintains | Buy | $250 → $270 |
| 5 Nov 2026 | Truist Securities | Reiterates | Buy | $241 → $261 |
| 21 Oct 2026 | TD Cowen | Reiterates | Buy | $250 |
| 19 Oct 2026 | Truist Securities | Maintains | Buy | $240 → $241 |
| 16 Oct 2026 | William Blair | Initiates | Outperform | — |
| 15 Oct 2026 | Needham | Reiterates | Buy | $275 |
| 14 Oct 2026 | RBC Capital | Maintains | Outperform | $259 → $260 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $251 → $259 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $239 → $240 |
| 28 Sept 2026 | Brookline Capital | Initiates | Buy | $318 |
| 24 Sept 2026 | Goldman Sachs | Reinstates | Buy | $267 |
| 21 Sept 2026 | B of A Securities | Maintains | Buy | $225 → $265 |
| 10 Sept 2026 | Morgan Stanley | Initiates | Overweight | $255 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RVMD.
This page is one stock. Monday covers all of them.
RVMD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RVMD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Revolution Medicines, Inc. returned +130.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RVMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 183.4×
- Price / book
- 15.1×
- EV / EBITDA
- —
Cheaper than 2% of US stocks
Cheaper than 5% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −93.6%
- Return on assets
- −32.1%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Revolution Medicines, Inc. has a market value of $34.5B and an enterprise value of $32.0B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$1.8B.
Diluted earnings per share, trailing twelve months: −$8.82.
Free cash flow in the twelve months to 30 June 2026: −$1.6B.
Revolution Medicines, Inc. employs 883 people.
Data provided by Twelve Data
RVMD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RVMD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Revolution Medicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RVMD
What is the RVMD stock price forecast for 2026-2027?
The 24 Wall Street analysts covering Revolution Medicines, Inc. have a median 12-month price target of $272, with estimates ranging from $179 to $350. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RVMD stock a buy right now?
Of the 24 analysts covering Revolution Medicines, Inc., 23 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Revolution Medicines, Inc. 56 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RVMD?
As at 21 Nov 2026, Revolution Medicines, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
Will RVMD stock go up?
No one can know that. What the data says: the median 12-month target from 24 analysts implies +68.6% from the last close, and Ticker Nerd's factor model ranks Revolution Medicines, Inc. 56 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RVMD stock forecast for 2030?
No analyst covering Revolution Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RVMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $179 to $350 over the next 12 months.
How has RVMD stock performed over the past year?
Revolution Medicines, Inc. returned +130.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Revolution Medicines, Inc. do?
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors.
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors. Its current pipeline includes RAS(ON) inhibitors and companion inhibitors being studied as monotherapies and in combination regimens to address cancers with specific RAS mutations and related pathway dependencies. Revolution Medicines concentrates on areas of high unmet medical need, including pancreatic, lung, and colorectal cancers, and its work is aimed at improving how these diseases are treated in modern oncology practice. Headquartered in Redwood City, California, and founded in 2014, Revolution Medicines occupies a specialized position in the biotechnology sector through its focus on advanced precision medicine approaches.
CEO Dr. Mark A. Goldsmith M.D., Ph.D. · 883 employees · United States · https://www.revmed.com